Giuliana Grossi

Regina Hartfield is the new CEO and president of the Sickle Cell Association of America. Listen to our interview with her to find out what's in store for 2022.

Baez-Sosa explains why further investigation of alloimmunization in patients with sickle cell disease is crucial.

Beach shares about Haywood's life, research, and impact on the sickle cell disease community after working alongside him at Johns Hopkins School of Medicine.

Achebe explains the promising results of the open label extension to the HOPE trial for patients with sickle cell disease.

Investigators examine the impact that 1 or 2 doses of dexamethasone has on morphine consumption and postoperative pain in patients undergoing a total knee arthroplasty.

Frank Peacock explains how methylnaltrexone can prevent patients with opioid-induced constipation from being hospitalized.

Investigators closely examine the differences between neuromuscular changes associated with normal aging and those associated with age-related disorders and how they affect individuals with knee osteoarthritis.

Phase 3 trial examines if adjusting the dose of hydroxyurea reduces the risk of stroke in children with sickle cell anemia.

New research published in The Journal of Emergency Medicine shows that methylnaltrexone is a great solution to opioid-induced constipation.

Accurate results can be obtained rapidly with this intuitive whole blood hemostasis system, allowing for efficient workflow at the point of care.

In this interview, Valton details the editing function of TALGlobin01 and how it stands out among traditional gene therapy approaches to sickle cell disease.

Björn Mellgård gets technical as he describes the function of TAK-755, the recombinant ADAMTS13 enzyme, in sickle cell disease and cTTP.

Greg Marchand has achieved world records in the field of OBGYN and minimally invasive surgery. In an interview, he discusses the progress of the outpatient hysteroscopy.

Investigators developed the first module to confront implicit bias toward patients with sickle cell disease on an individual or personal level.

Novartis receives approval for Cosentyx, their biologic treatment for enthesitis-related arthritis and juvenile psoriatic arthritis, in children and adolescents.

The American Society of Hematology debuted its Health Equity Rounds series, which are interactive, case-based discussions with an interdisciplinary panel to include hematologists, health equity/public health experts, patients, and patient advocates.

The clinical program has been suspended for patients that are under the age of 18 after an adolescent patient developed persistent anemia.

Fuad El Rassi talks about the Grady Comprehensive Sickle Cell center, the COVID-19 vaccine, and the data he presented at ASH.

TAK-755, a recombinant ADAMTS13, is examined for its therapeutic benefit to patients with sickle cell disease and patients with cTTP.

Of the SCD patients who contracted COVID-19, 49% of them visited the Grady Comprehensive Sickle Cell center because of a vaso-occlusive event.

New research on the preclinical product TALGlobin01 reveals the potential impact that gene therapy can have on the future of sickle cell disease treatment.

The global biopharmaceutical company released research data on rozanolixizumab and zilucoplan at the 2021 ASH annual meeting and exposition.

Shaji Kumar, MD, presents final Phase 3 data of the BELLINI trial at the ASH 2021 conference.

Among vaccinated individuals, results show a 90% lower mortality rate due to COVID-19 in the group that received a booster compared with those who did not.

Promising results show that high-flow oxygen therapy is more effective in treating patients with severe COVID-19 than conventional methods like invasive mechanical ventilation.

Investigators found about 70% of rheumatology patients had a good antibody response to the COVID-19 vaccines.

Guselkumab is the first and only selective interleukin inhibitor therapy in the US that's approved for both moderate-severe plaque psoriasis and active psoriatic arthritis regardless of prior TNFi exposure.

This study evaluates the likelihood that young adults with sickle cell disease or sickle cell trait will have a child or expand their family.

A correlation between disease activity and overall hand functionality was discovered in patients with psoriatic arthritis.

In this video interview, Titilope Fasipe shares a summary of her plenary presentation on sickle cell disease from the National Organization for Rare Disease summit.